Step by Step

INTRODUCTION

ABIM MOC Activity ID

11/7/2023 - Medical Grand Rounds: Bench to Bedside - COPD mechanisms to clinical practice at the dawn of precision medicine

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

    • Review the knowledge gap in COPD research
    • Discuss recent advances in COPD research  
    • Describe potential regenerative therapy approaches
    • Review new clinically relevant tissue models to foster precision medicine approaches
    • Explain the variation in disease pattern and progression in COPD.
    • Examine the current guideline based therapy limits and the unmet need. 
    • Evaluate current available and projected future approaches to precision medicine 


Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

  • Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Stolz D, Mkorombindo T, Schumann DM, Agusti A, et al. Lancet. 2022 Sep 17;400(10356):921-972. doi: 10.1016/S0140-6736(22)01273-9. Epub 2022 Sep 5. PMID: 36075255 Review. Am J Respir Crit Care Med. 2012 Dec 15;186(12):1213-9.  doi: 10.1164/rccm.201207-1151PP. Epub 2012 Sep 20.
  • Endogenous lung regeneration: potential and limitations Jason Rock  1 , Melanie Königshoff. Lung regeneration: a tale of mice and men. Basil MC, Morrisey EE.  Semin Cell Dev Biol. 2020 Apr;100:88-100. doi: 10.1016/j.semcdb.2019.11.006. Epub 2019 Nov 21. 
  • Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J 2023; 61: 2300239 DOI: 10.1183/13993003.00239-2023
  • Riley CM, Sciurba FC. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA. 2019 Feb 26;321(8):786-797. doi: 10.1001/jama.2019.0131. 
  • Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al; BOREAS Investigators. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. PMID: 37272521
  • Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. 


Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME).


The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™.Each physician should only claim credit commensurate with the extent of their participation in the activity.


Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:
Frank C. Sciurba, MD — Associate Professor of Medicine at the University of Pittsburgh School of Medicine; Medical Director of the Pulmonary Physiology Laboratory in the Division of Pulmonary, Allergy and Critical Care Medicine
Dr. Sciurba receives grant/research support from Sanofi/Regeneron, AstraZeneca, Verona Pharma, Nuvaira, Gala Therapeutics, Pulmonx, NIH, AHRQ, COPD Foundation. He is a consultant for Sanofi/Regeneron, AstraZeneca,, GlaxoSmithKline (GSK), and Boehringer Ingelheim.
Melanie Koenigshoff, MD, PhD — Visiting Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine; Associate Chief of Research, Division of Pulmonary, Allergy and Critical Care Medicine University of Pittsburgh
No planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.